Reasons Given by Women for Discontinuing the Use of Progestogen Implants at Koster Hospital, North West Province

Overview

Journal S Afr Fam Pract (2004)

Specialties General Medicine
Public Health

Date 2022 Nov 4

PMID 36331205

Authors

Bolarinwa T Olaifa

Henry I Okonta

Justin B Mpinda

Indiran Govender

Affiliations

Soon will be listed here.

Abstract

Background: In 2014, the South African National Department of Health introduced a new addition to the long-acting reversible contraceptive (LARC) options available in the country. This was a single rod subdermal progestogen implant (Implanon®NXT) which provided 3 years of effective contraception cover. However, the new contraceptive device uptake and general acceptance amongst women quickly diminished, with a slew of requests for its removal. The aim of this study was to explore the reasons given by women for discontinuing the use of their progestogen implants at Koster Hospital, North West province, South Africa.

Methods: A qualitative study was conducted using semistructured interviews. Thirteen women were purposively selected and interviewed at Koster Hospital Family Planning Unit. The transcriptions of the audio-taped interviews were analysed thematically.

Results: The following themes emerged from the interviews as reasons the women discontinued their progestogen implants: side effects such as menstrual problems, arm discomfort and weight gain. Other themes were family or social factors and the desire to conceive.

Conclusion: The reasons for discontinuation of Implanon by women at Koster Hospital were the undesirable side effects they experienced whilst using the contraceptive device. These side effects were mainly menstrual problems, arm discomfort and weight gain. Family and other social dynamics also influenced some of the participants' decision to discontinue their contraceptive implants.

References

Qiu M, Juarez J, de Carvalho A, Juliana F, Nhamba L, Neves I . Contraceptive Implant Discontinuation in Huambo and Luanda, Angola: A Qualitative Exploration of Motives. Matern Child Health J. 2017; 21(9):1763-1771. DOI: 10.1007/s10995-017-2349-1. View

Prata N, Bell S, Fraser A, Carvalho A, Neves I, Nieto-Andrade B . Partner Support for Family Planning and Modern Contraceptive Use in Luanda, Angola. Afr J Reprod Health. 2018; 21(2):35-48. DOI: 10.29063/ajrh2017/v21i2.5. View

Krefting L . Rigor in qualitative research: the assessment of trustworthiness. Am J Occup Ther. 1991; 45(3):214-22. DOI: 10.5014/ajot.45.3.214. View

Saeed A, Narayan N, Pandya A . Contraceptive Implant-Related Acute Ulnar Neuropathy: Prompt Diagnosis, Early Referral, and Management Are Key. Eplasty. 2018; 18:e28. PMC: 6174575. View

Flore M, Chen X, Bonney A, Mullan J, Dijkmans-Hadley B, Hodgkins A . Patients' perspectives about why they have their contraceptive Implanon NXT device removed early. Aust Fam Physician. 2016; 45(10):740-744. View

Kumar N, Brown J . Access Barriers to Long-Acting Reversible Contraceptives for Adolescents. J Adolesc Health. 2016; 59(3):248-253. DOI: 10.1016/j.jadohealth.2016.03.039. View

Mansour D, Korver T, Marintcheva-Petrova M, Fraser I . The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care. 2008; 13 Suppl 1:13-28. DOI: 10.1080/13625180801959931. View

Mabuza L, Govender I, Ogunbanjo G, Mash B . African Primary Care Research: qualitative data analysis and writing results. Afr J Prim Health Care Fam Med. 2015; 6(1):E1-5. PMC: 4502868. DOI: 10.4102/phcfm.v6i1.640. View

Grunloh D, Casner T, Secura G, Peipert J, Madden T . Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol. 2013; 122(6):1214-21. PMC: 4051392. DOI: 10.1097/01.AOG.0000435452.86108.59. View

10.

Higgins J . Pregnancy Ambivalence and Long-Acting Reversible Contraceptive (LARC) Use Among Young Adult Women: A Qualitative Study. Perspect Sex Reprod Health. 2017; 49(3):149-156. PMC: 5597464. DOI: 10.1363/psrh.12025. View

11.

Lopez L, Bernholc A, Chen M, Grey T, Otterness C, Westhoff C . Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 2016; (8):CD008452. PMC: 9063995. DOI: 10.1002/14651858.CD008452.pub4. View

12.

Alemayehu M, Belachew T, Tilahun T . Factors associated with utilization of long acting and permanent contraceptive methods among married women of reproductive age in Mekelle town, Tigray region, north Ethiopia. BMC Pregnancy Childbirth. 2012; 12:6. PMC: 3297532. DOI: 10.1186/1471-2393-12-6. View

13.

Meskele M, Mekonnen W . Factors affecting women's intention to use long acting and permanent contraceptive methods in Wolaita Zone, Southern Ethiopia: a cross-sectional study. BMC Womens Health. 2014; 14:109. PMC: 4237819. DOI: 10.1186/1472-6874-14-109. View

14.

Joshi R, Khadilkar S, Patel M . Global trends in use of long-acting reversible and permanent methods of contraception: Seeking a balance. Int J Gynaecol Obstet. 2015; 131 Suppl 1:S60-3. DOI: 10.1016/j.ijgo.2015.04.024. View

15.

Inoue K, Kelly M, Barrett A, Bateson D, Black K, Stewart M . Australian women's experiences of the subdermal contraceptive implant: A qualitative perspective. Aust Fam Physician. 2016; 45(10):734-739. View

16.

Aisien A, Enosolease M . Safety, efficacy and acceptability of implanon a single rod implantable contraceptive (etonogestrel) in University of Benin Teaching Hospital. Niger J Clin Pract. 2010; 13(3):331-5. View

17.

Abdel-Aleem H, dArcangues C, Vogelsong K, Gaffield M, Gulmezoglu A . Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev. 2013; (10):CD003449. DOI: 10.1002/14651858.CD003449.pub5. View

18.

Brown M, Britton J . Neuropathy associated with etonogestrel implant insertion. Contraception. 2012; 86(5):591-3. DOI: 10.1016/j.contraception.2012.05.014. View

19.

Diego D, Tappy E, Carugno J . Axillary migration of Nexplanon®: Case report. Contraception. 2016; 95(2):218-220. DOI: 10.1016/j.contraception.2016.11.002. View

20.

Jacobstein R, Polis C . Progestin-only contraception: injectables and implants. Best Pract Res Clin Obstet Gynaecol. 2014; 28(6):795-806. DOI: 10.1016/j.bpobgyn.2014.05.003. View